← back to search

Shigeru Chiba

University of Tsukuba · JP
Area of research
Hematology · Pathology and Forensic Medicine
Research interest
Research interests include Acute Myeloid Leukemia Research, Lymphoma Diagnosis and Treatment, Hematopoietic Stem Cell Transplantation, and Myeloproliferative Neoplasms: Diagnosis and Treatment.
h-index
78
citations
29,844
works
762
NIH funding
primary concept
Medicine
email

Recent publications

Cardiac Reprogramming and Gata4 Overexpression Reduce Fibrosis and Improve Diastolic Dysfunction in Heart Failure With Preserved Ejection Fraction.
2025cited by 19position: contributordoi
Romiplostim with ciclosporin A in patients with aplastic anaemia naïve to immunosuppressive therapy: A phase 2/3 study.
2025cited by 3position: contributordoi
Identification and replication of sex-dimorphic protein quantitative trait loci across multiple ancestries and their associations with diseases.
2025cited by 2position: contributordoi
Comparison of severe aplastic anaemia and lower risk hypoplastic myelodysplastic neoplasms: Critical role of megakaryocyte count in distinguishing aplastic anaemia from myelodysplastic neoplasms.
2025cited by 1position: contributordoi
Recent progress in clonal hematopoiesis: expanding the concept.
2025cited by 0position: contributordoi
Clones in blood and stratified epithelial cells, and their drivers.
2025cited by 0position: contributordoi
Genetic analysis of myeloid neoplasms with der(1;7)(q10;p10).
2025cited by 0position: contributordoi
Clinical impact and characteristics of erythroid dysplasia in adult aplastic anaemia: Results from a multicentre registry.
2024cited by 1position: contributordoi
Association between microenvironment-related genes and prognosis of primary central nervous system lymphoma.
2024cited by 0position: contributordoi
Germ line DDX41 mutations define a unique subtype of myeloid neoplasms.
2023cited by 116position: contributordoi
Direct Reprogramming Improves Cardiac Function and Reverses Fibrosis in Chronic Myocardial Infarction.
2023cited by 98position: contributordoi
Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms.
2023cited by 23position: contributordoi
The fatty acid elongase Elovl6 is crucial for hematopoietic stem cell engraftment and leukemia propagation.
2023cited by 9position: contributordoi
A longitudinal analysis of paroxysmal nocturnal haemoglobinuria-type cells in patients with bone marrow failure: Results of a prospective multi-centre study in Japan.
2023cited by 2position: contributordoi
Repeated immunosuppressive rabbit antithymocyte globulin therapy for adult patients with relapsed or refractory aplastic anemia.
2023cited by 2position: contributordoi
Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Supplementary Figure from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Data from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Supplementary Table from Amplified <i>EPOR</i>/<i>JAK2</i> Genes Define a Unique Subtype of Acute Erythroid Leukemia
2023cited by 0position: contributordoi
Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
NEJM Evidence 2022cited by 794position: middledoi
Germ line<i>DDX41</i>mutations define a unique subtype of myeloid neoplasms
Blood 2022cited by 140position: middledoi
Follow-up of patients with R/R <i>FLT3-</i>mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial
Blood 2022cited by 136position: middledoi
Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial.
2022cited by 112position: contributordoi
A single-cell atlas of non-haematopoietic cells in human lymph nodes and lymphoma reveals a landscape of stromal remodelling.
2022cited by 91position: contributordoi
Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia.
2022cited by 21position: contributordoi
Retrospective analyses of other iatrogenic immunodeficiency-associated lymphoproliferative disorders in patients with rheumatic diseases.
2021cited by 10position: contributordoi
Author Correction: Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Nature Medicine 2021cited by 4position: middledoi
Advances in understanding of angioimmunoblastic T-cell lymphoma.
2020cited by 133position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 23 papers (2019–2025) · 8 papers (2020–2023)Mamiko Sakata‐Yanagimoto · University of Tsukuba Hospital8 papers (2020–2023)Tatsuhiro Sakamoto · University of Tsukuba4 papers (2022–2024)Yasuhito Suehara · University of Tsukuba4 papers (2019–2023)Keiichiro Hattori · University of Tsukuba4 papers (2019–2024)Shinji Nakao · Kanazawa University4 papers (2023–2025)Naoshi Obara · Springer Nature3 papers (2019–2023)Hidekazu Nishikii · Springer Nature3 papers (2019–2023)Seishi Ogawa · Institute for Advanced Study3 papers (2020–2023)Yasushi Miyazaki · Tenri Hospital2 papers (2024–2025)Junya Kanda · Japan Advanced Institute of Science and Technology2 papers (2024–2025)Akifumi Takaori-Kondo · Kobe University2 papers (2023–2023)Takayasu Kato · University of Tsukuba2 papers (2023–2023)Yoshiaki Abe · University of Tsukuba2 papers (2022–2024) · 2 papers (2023–2023)Naoki Kurita · University of Tsukuba2 papers (2019–2023) · 2 papers (2023–2023)Kota Fukumoto · University of Tsukuba Hospital2 papers (2020–2020)Tomoya Maeda · Saitama International Medical Center2 papers (2024–2025)